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Bardet-Biedl syndrome (BBS) is an uncommon multisystemic disorder characterized primarily by retinal dystrophy,
obesity, polydactyly, and renal dysfunction. BBS has been modeled historically as an autosomal recessive trait,
under which premise six independent BBS loci (BBS1–BBS6) have been mapped in the human genome. However,
extended mutational analyses of BBS2 and BBS6, the first two BBS genes cloned, suggest that BBS exhibits a more
complex pattern of inheritance, in which three mutations at two loci simultaneously are necessary and sufficient
in some families to manifest the phenotype. We evaluated the spectrum of mutations in the recently identified BBS4
gene with a combination of haplotype analysis and mutation screening on a multiethnic cohort of 177 families.
Consistent with predictions from previous genetic analyses, our data suggest that mutations in BBS4 contribute to
BBS in !3% of affected families. Furthermore, integrated mutational data from all three currently cloned BBS
genes raise the possibility that BBS4 may participate in triallelic inheritance with BBS2 and BBS1, but not the other
known loci. Establishment of the loci pairing in triallelism is likely to be important for the elucidation of the
functional relationships among the different BBS proteins.
Introduction
Genetic disorders have historically been divided into
Mendelian and complex traits, the former involving
mutational events at one locus (or, in the case of con-
tiguous-gene syndromes, genomic rearrangements over
a defined region of the genome) and the latter requiring
mutations at more than one gene, coupled with envi-
ronmental and/or stochastic factors, to manifest the
phenotype. Recent studies have suggested that some
disorders bridge these two categories to establish a con-
tinuum of mutational mechanisms, whereby the com-
binatorial effect of mutations at distinct loci is neces-
sary and sufficient for pathogenicity.
Bardet-Biedl syndrome (BBS [MIM 209900]) appears
to be an important example of this model of phenotype
transmission, since it can be inherited both as an auto-
somal recessive trait and as an oligogenic trait. BBS pres-
ents as a complex phenotype, with substantial inter- and
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intrafamilial variability, characterized by the clinical fea-
tures of retinal dystrophy, obesity, polydactyly, hypogo-
nadism, and renal dysplasia. Less frequent features in-
clude short stature, relative or absolute macrocephaly,
diabetes mellitus, cardiomyopathy or congenital cardiac
malformations, reproductive-tract anomalies, develop-
mental retardation, and speech and behavioral anomalies
(Green et al. 1989; Beales et al. 1999; Katsanis et al.
2001a). The segregation of BBS in families and popu-
lation isolates initially led to the hypothesis that the dis-
order is inherited as a genetically heterogeneous auto-
somal recessive trait. On the basis of this model, six BBS
loci have been identified: BBS1, on 11q13 (Leppert et al.
1994); BBS2, on 16q21 (Kwitek-Black et al. 1993);
BBS3, on 3p12 (Sheffield et al. 1994);BBS4, on 15q22.2-
q23 (Carmi et al. 1995); BBS5, on 2q31 (Young et al.
1999); and BBS6, on 20p12 (Katsanis et al. 2000). We
have also reported evidence for at least one more locus
in the human genome (Beales et al. 2001). However, mu-
tational analysis of the first two cloned BBS genes—
BBS2, which encodes a protein of unknown function
(Nishimura et al. 2001), and BBS6, which encodes a
putative chaperonin (Katsanis et al. 2000; Slavotinek et
al. 2000)—suggested that, in some families, the disorder
may be inherited in a complex fashion, since the phe-
notype requires that two “recessive” mutations at one
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locus be paired with a third mutation at another locus,
a phenomenon termed “triallelic inheritance” (Katsanis
et al. 2001a, 2001b).
Since the first demonstration of this complex mode
of inheritance, a third BBS locus, BBS4, has been iden-
tified with homology to the O-linked acetylglucosamine
transferase (OGT) family of genes (Mykytyn et al. 2001).
Here, we have evaluated, irrespective of locus assign-
ment on the basis of either haplotype or other mutation
data for each family, a cohort of 177 families with
BBS, to identify mutations in BBS4. As predicted
from our earlier genetic analyses, BBS4 contributes
the least to BBS, although its prevalence is substan-
tially higher among Arab families than among white
families from Europe and North America. We also
suggest that BBS4 may exhibit complex inheritance
in which both recessive- and dominant-susceptibility
mutations at BBS4 are paired with mutations at
BBS2, BBS1, or another, as-yet-unidentified locus in
the human genome, to cause the disease phenotype.
Patients and Methods
Patients
One hundred seventy-seven families with BBS, of var-
ious ethnic origins, were screened formutations inBBS4.
The diagnosis of BBS was based on the established cri-
terion that four of six cardinal features must be present
(Beales et al. 1999). In several cases, the diagnosis was
ascertained by local physicians and was verified through
extensive examination of medical records, by one or
more of the coauthors (R.A.L., H.K., and/or P.L.B.).
Blood was obtained with consent, in accordance with
protocols approved by the appropriate human-subjects
ethics committees at each institution, and DNA was ex-
tracted by a salting-out process (Puregene and Gentra
Systems).
Mutational and Genetic Analysis
The genomic structure of BBS4 was discerned by
alignment of the BBS4 cDNA (GenBank accession
number XM_027370) to genome assembly scaffold
NT_010298 with the nucleotide-nucleotide BLAST
(blastn) algorithm and the GCG software package,
as described elsewhere (Katsanis et al. 1997, 2000).
Primers were designed for the amplification of each
of the 17 BBS4 exons (for primers, see the Lupski Lab
Web site), and direct sequencing of BBS4 was per-
formed as described elsewhere (Katsanis et al. 2000).
For the genetic analyses, fluorescent microsatellite
STRPs were genotyped for each family member, and
haplotypes were constructed across each BBS locus,
as described elsewhere (Beales et al. 1999; Katsanis
et al. 1999). Microsatellite sequences were obtained
from either the Genome Database or the Whitehead
Institute Center for Genome Research.
Identification of BBS4 Homologs
To identify the mouse ortholog of BBS4, we used
the human BBS4 peptide sequence to screen the mouse
subdivision of the Expressed Sequence Tags Database
(dbEST). The sequence of positive cDNAs were down-
loaded and were assembled into a contig, as described
elsewhere (Katsanis and Fisher 1998). Clones were
obtained from Research Genetics and were sequenced
by dye-terminator chemistry (Applied Biosystems).
Gaps in the sequence were closed by a BLAST search
of the mouse-genome-sequence database. Validation
of the contiguity of the mouse message was achieved
by cDNA amplification and the sequencing of PCR
products from a mouse-cDNA panel (Clontech).
We identified the Drosophila and thermobacterial
homologs of BBS4 by searching Swissprot, Flybase,
and the Celera Genomics databases with the human
peptide sequence. Sequences were aligned with the
Bestfit, Gap, and Pileup programs from the GCG, ver-
sion 9.0, sequence-analysis computer package (Uni-
versity of Wisconsin).
Results
Mutation Analysis of BBS4
Studies based on haplotype-inferred locus assignment
(HILA) have predicted that BBS4 is a minor contributor
to BBS, since only 1%–2% of families showed chro-
mosomal inheritance across the BBS4 region consistent
with two-allele segregation and linkage to that locus
alone (Beales et al. 2001). The recent cloning of BBS4
has enabled us to evaluate this prediction and to inves-
tigate the mutational spectrum of this gene. We se-
quenced, irrespective of HILA, all exons and splice junc-
tions of BBS4, in 177 independent probands of various
ethnic origins. We detected numerous alterations, which
we evaluated by investigating whether (a) the nucleotide
change either substituted a nonconservative amino acid,
interrupted translation, or predicted altered mRNA pro-
cessing; (b) the alteration was not found in a minimum
of 192 ethnically matched control chromosomes and 96
random control chromosomes; and (c) the candidatemu-
tation segregated with the disease within the family. The
latter criterion was restricted by the possibility that BBS
mutations do not necessarily follow a strict Mendelian
pattern of inheritance, since it is possible to inherit two
BBS mutations at a single locus but fail to manifest a
phenotype (Katsanis et al. 2001a). Nevertheless, it seems
unlikely that both a conventional recessive model and a
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Table 1
Summary of BBS4 Mutations
Family Mutation 1 Mutation 2 Mutation 3
KK021 IVS3-2ArG IVS3-2ArG
PB043 A364E (BBS4) A364E (BBS4) T558I (BBS2)a
AR153 L327P BBS1? BBS1?
AR708 N165H Unknown Unknown
AR717 S457I Unknown Unknown
a Although three mutant alleles are listed, the affected individual
(PB043-01) in family PB043 carries four potential mutations, since he
is homozygous for both A364E and T558I.
triallelic model of disease inheritance would manifest in
the same family—that is, a situation in which two mu-
tations at a single locus would be sufficient to cause
disease in some but not all affecteds within a single fam-
ily. Therefore, we reasoned that the same disease-asso-
ciated mutations, irrespective of the number of BBS loci
required for disease manifestation, must be inherited by
all affected individuals of any given sibship, and, thus,
we restricted segregation analyses only to affected sub-
jects with BBS.
Alterations in five families fulfilled our three minimal
criteria for pathogenicity. We identified two BBS4 mu-
tations in two families (KK021 and PB043), and we de-
tected only a single mutant allele by sequencing in three
other families (AR153, AR708, and AR717) (table 1).
Because a deletion of exons 2–4 has also been associated
with the disease (Mykytyn et al. 2001), we also performed
long-range PCR in all 177 patients, to amplify a 7-kb
genomic fragment between introns 1 and 4. To investigate
the possibility that there are other small deletions at this
locus, we also analyzed 12 SNPs across theBBS4 genomic
region (table 2). Neither approach suggested the presence
of deletions. In all patients, we either amplified only the
correct-sized amplicon or inferred, on the basis of het-
erozygosity at polymorphic positions, that there were two
alleles (data not shown).
Recessive Inheritance of Mutations in BBS4
Affected individual KK021-10, from consanguineous
Saudi Arabian family KK021, is homozygous for an
ArG transition at the acceptor splice site of exon 4
(IVS3-2ArG) (fig. 1 and table 1). This alteration is likely
to be a pathogenic mutation, since it was not found in
108 ethnically matched control chromosomes and is pre-
dicted to result in a null allele due to missplicing and
subsequent nonsense-mediated RNA decay (Losson and
Lacroute 1979). Direct sequencing of the DNA from all
available members of this family revealed that individual
KK021-10 inherited one mutant allele from each parent.
Consistent with a recessive model of disease inheritance,
we found that all other available unaffected familymem-
bers either were heterozygous or had the wild-type allele
at this site (fig. 1). These data concur with our genetic
prediction that BBS in family KK021 is due to a ho-
mozygous BBS4 mutation, since this family both exhib-
ited identity-by-descent (IBD) across the BBS4 region
and was excluded from all other known BBS loci by
haplotype analysis.
A homozygous alteration was also detected in fam-
ily PB043, a consanguineous sibship of Kurdish ori-
gin. The only affected individual (PB043-01) inherited
one 1091CrA mutation from each parent, which, on
conceptual translation, would result in an A364E al-
teration, a potentially deleterious change in the local
polarity of the polypeptide. Consistent with our hy-
pothesis that this alteration is a disease-causing muta-
tion, we did not detect the A364E allele in 384 control
chromosomes (including 84 Kurdish chromosomes).
Furthermore, segregation of this allele, both by se-
quencing and by restriction analysis, indicated that
only the affected individual (PB043-01) was homo-
zygous at this locus, whereas two unaffected sibs who
were tested were carriers. These observations are con-
sistent with a traditional model of autosomal recessive
transmission and are concordant with previous ge-
netic data that had excluded family PB043 from all
other BBS loci by haplotype analysis.
In North American families AR153, AR708, and
AR717, we were able to identify a single alteration
in BBS4 (table 1). Without functional data on the
BBS4 protein, the pathogenicity of these alterations is
unclear. However, each mutation is predicted to result
in a nonconservative amino acid substitution that
would change either the local charge (N168H in
AR708), the hydrophobicity (S457I in AR717), or the
secondary structure (L327P in AR153). Also, each
mutation occurred in both affected family members
and did not occur in 384 ethnically matched control
chromosomes and 96 random control chromosomes.
Evolutionary Conservation of BBS4 Mutation Sites
To evaluate further the pathogenic potential of each
missense alteration in BBS4, we ascertained the evolu-
tionary tolerance for variation at each amino acid po-
sition. Using the BBS4 amino acid sequence, we per-
formed a BLAST search of all subdivisions of both
dbEST and the Drosophila genome database. We iden-
tified multiple bovine, mouse, and Drosophila ESTs,
which we assembled into discrete contigs and compared
to the human genomic sequence. Conceptual translation
of each contig and alignment to the human BBS4 amino
acid sequence suggested that we had identified the com-
plete coding sequence of the mouse (89.9% identity and
92.1% similarity) ortholog of BBS4 and partial se-
quences of Drosophila (36.7% identity and 49.1% sim-
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Figure 1 Recessive inheritance of IVS3-2ArG, an exon 4 splice-
acceptor mutation, in Saudi Arabian family KK021.
Table 2
Summary of Other Variations
Exon Position Variation Comment
1 17 C/A
1 42 G/A A allele present in 1 patient and in 0/84 control subjects
3 6 A/G G allele present in 1 patient and in 0/81 control subjects
4 91 G/A
5 8 A/C C allele present in 1 patient and in 0/93 control subjects
5 28 insA
6 17 C/T
13a c.1061 C/T
20 C/T
15 18 C/T C allele present in 1 patient and in 0/93 control subjects
16 45 C/T
16a c.1561 G/C C allele present in 1 patient and in 0/87 control subjects
a SNPs, annotated by the position in the cDNA sequence, where the first base of the start methionine
is base 1.
ilarity) and bovine (92.4% identity and 93.5% similar-
ity) orthologs.
We compared all BBS4 peptide sequences to each other
and to the amino acid sequence of a more distantly re-
lated Methanothermobacter thermautotrophicus OGT
(GenBank accession number NC_000916; 35.7% sim-
ilarity to the human BBS4 peptide sequence). Evaluation
of the four mutated residues revealed substantial inter-
species conservation (fig. 2): the asparagine residue at
position 165 of the human sequence was conserved in
both mammalian species, as well as M. thermautotro-
phicus; the leucine residue at position 327 and the al-
anine residue at position 364 were conserved in mam-
mals and insects; and the serine residue at position 457
could be evaluated only in mouse, which also contains
a serine at this position.
Does BBS4 Also Exhibit Complex Inheritance?
Both the conservation of the mutated amino acids in
lower organisms and the presence of these alterations in
all affected individuals (but not in 384 control chro-
mosomes) suggest that these changes represent patho-
genic alleles, rather than benign polymorphisms. Al-
though we detected no deletions by long-range PCR and
SNP analysis, we cannot exclude the possibility that a
second mutant BBS4 allele may map to a regulatory
region of the genomic locus or may occur with another
local rearrangement that is not detectable by these tech-
niques. We therefore examined the haplotypes at all six
known BBS loci in all five families in which we found
at least one mutant BBS4 allele, including the two sib-
ships in which both alleles were found. The segregation
of the extended haplotypes in families KK021 and
PB043 is consistent with linkage to BBS4, but AR717
is too small for definitive assignment by HILA.However,
we were able to exclude recessive inheritance of BBS4
mutations in families AR153 and AR708. In family
AR708, both the affected sib and the unaffected sib in-
herited the same parental BBS4 chromosomes. In family
AR153, the two affected sibs had inherited the same
paternal chromosome (carrying the L327Pmutation) but
a different maternal chromosome (fig. 3A). Therefore,
if the mother (AR153-02) was a carrier for a BBS4 mu-
tation that was undetectable by sequencing, then she
could not have transmitted the mutant allele to both of
her children. Further haplotype analysis indicated that
family AR153 could be excluded from all loci except
BBS1, raising the possibility that a single L327P mu-
tation in BBS4 may act in conjunction with two BBS1
mutations (fig. 3A).
We have previously reported several instances in
which mutations that, at first, appear to segregate in a
traditional recessive fashion are determined, when ad-
ditional genes become available for testing, to be trial-
lelic (Katsanis et al. 2001a). Therefore, we integrated all
sequence data from our earlier mutation screenings at
BBS2 and BBS6, irrespective of the initial HILA for each
of the five families with BBS4 mutations. Although four
of the families had the wild-type allele for each of the
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Figure 2 Evolutionary conservation of residues involved in complex inheritance of BBS. A, Alignment of BBS4 amino acid sequences of
human (Hsa), mouse (Mmu), bovine (Bta), and Drosophila (Dme). Mutant alleles, indicated by asterisks (*), are named above the sequence.
Because of a substantial sequence divergence, the amino acid sequence of an M. thermautotrophicus (Mth) OGT is shown only at the residues
mutated in BBS. The predicted tetratricopeptide domain is boxed. B, Alignment, at residues 547–566, between human BBS2 peptide sequence
and mouse, rat (Rno), and zebrafish (Dre) BBS2 peptide sequence, to illustrate the evolutionary conservation of the threonine residue at position
558. Note that T558I has previously been reported as T560I (Katsanis et al. 2001a).
other BBS genes, the affected individual (PB043-01) in
consanguineous family PB043 was homozygous for a
T558I mutant BBS2 allele. Segregation of this allele by
both sequencing and restriction analysis suggested that
three unaffected sibs (PB043-03, PB043-04, and PB043-
05) and the mother (PB043-07) were homozygous for
this alteration in BBS2. These data suggest either that
T558I is a benign, albeit rare, polymorphism, in which
case family PB043 would represent an example of clas-
sical Mendelian inheritance, or that the disease is in-
herited in this family in a tetra-allelic fashion (fig. 3B).
Both an unaffected sib (PB043-04) and the mother
(PB043-07) carry three BBS mutations (a homozygous
T558I mutation, in BBS2, and a heterozygous A364E
mutation, in BBS4), thereby implying that, if the T558I
mutation in BBS2 is pathogenic, then four mutant alleles
may be both necessary and sufficient for the manifes-
tation of BBS in this family. Despite both the absence of
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Figure 3 Examples of complex inheritance involving BBS4 and other loci. “wt” denotes wild type. A, Potential triallelic inheritance
between BBS1 and BBS4, in family AR153. This family is genetically excluded from the inheritance of recessive BBS4 mutations and bears
haplotypes consistent with linkage across BBS1, yet both patients inherited a heterozygous L327P BBS4 mutation. B, Potential tetra-allelic
inheritance between BBS2 and BBS4, in family PB043. The affected individual (PB043-01) has inherited a homozygous T558I BBS2 mutation
and a homozygous A364E BBS4 mutation. Confirmation, by restriction analysis, of mutations in family PB043 is also shown: the T558I allele
generates 68-bp and 175-bp SspI fragments, whereas the A364E allele generates a 33-bp MboI fragment.
the T558I alteration from 192 control chromosomes and
the evolutionary conservation of the threonine residue
at position 558 (fig. 2B), functional assays will be re-
quired to clarify the potentially pathogenic role of this
alteration and, consequently, the mode of inheritance in
this family.
Discussion
We report a mutation screening of BBS4, the third of at
least six BBS genes in the human genome, in a large,
multiethnic patient cohort. As predicted from earlier ge-
netic linkage/haplotype analyses, BBS4 is a minor con-
tributor to BBS, since only 5/177 (∼2.8%) families har-
bor BBS4 mutations. The substantial size and diversity
of the North American/European cohort that we studied
suggest that BBS4 contributes less in these populations
than in populations of Middle Eastern origin. Only 3/
146 (2.05%) North American/European families carry
at least one BBS4mutation—compared to 2/31 (6.45%)
Arab and Kurdish families (although the sample size of
the latter is not large enough to draw statistically sig-
nificant conclusions).
We also report that BBS4mutations may be inherited
in a complex, as well as autosomal recessive, pattern.
Two families that harbor a single heterozygous BBS4
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mutation could be excluded genetically from the inher-
itance of recessive BBS4mutations, whereas the affected
individual in a third family had inherited fourmutations
(a homozygous T558I mutation, in BBS2, and a ho-
mozygous A364E mutation, in BBS4). Unlike the BBS2
and BBS6mutational pairs, in which at least one family
segregated two null alleles at one locus and a third null
allele at the second locus (Katsanis et al. 2001a), un-
equivocal establishment of triallelism for BBS4 is con-
founded by the fact that all non-Mendelian candidate
susceptibility mutations detected in our screenings are
missense. Other than the similarities between OGTs and
BBS4 alterations and the predicted presence of a tetra-
tricopeptide motif toward the amino-terminus of the
BBS4 protein (Mykytyn et al. 2001), no functional data
assist the evaluation of the effect of these BBS4 alter-
ations. Both the conservation across phyla (including
the evolutionarily remote insect and thermobacterial
species) of the mutated residues and the absence of these
alterations from control chromosomes support the hy-
pothesis that these amino acid substitutions are path-
ogenic mutations. The probability that we have detected
BBS4 carriers by chance alone is negligible. Given BBS’s
frequency of 1:125,000–1:150,000 and the ∼3% con-
tribution of BBS4, the detection of three heterozygous
carriers in 177 families represents a statistically sig-
nificant deviation from the expected carrier frequency
of 1:5900–1:6400 for BBS4 ( ; ).2 4x p 299.1 P ! 10
These data therefore suggest that BBS4 may partici-
pate in complex inheritance with other BBS loci, such
as BBS1 (in family AR153), BBS2 (in family PB043),
and another, unmapped BBS locus (in family AR708).
Nevertheless, this genetic model requires independent
substantiation by the establishment of the biochemical
and/or cellular effect(s) of these alterations.
Our mutation analyses of BBS4 also indicate that, in
some instances, more than three mutant alleles may be
required for the manifestation of disease. In family
PB043, the affected individual (PB043-01) carries two
homozygous mutations and is IBD across both theBBS2
and the BBS4 genomic regions. An unaffected sib
(PB043-04) and the mother (PB043-07) are carriers for
three mutations (two BBS2 mutations and one BBS4
mutation) and are clinically normal, thereby suggesting
that a fourth mutation, in this instance, may be nec-
essary and sufficient to cause the phenotype. If theBBS2
T558I allele is a benign polymorphism, then this family
segregates the A364E allele in a Mendelian recessive
fashion. Alternatively, however, perhaps the T558I mu-
tation is mild, but its effect is unmasked and/or exac-
erbated by the presence of additional mutations. Such
examples are likely to be rare, because any offspring
has only a 1/16 chance to inherit all four mutant chro-
mosomes; however, consanguinity would escalate that
likelihood.
Assessment of complex inheritance in BBS is essential
both to understand the molecular pathogenesis of this
syndrome and to construct models for disorders that
bridge Mendelian and complex traits. Our observation
of potential multiallelism between BBS4 and two other
known BBS loci, BBS1 andBBS2,may havemechanistic
importance, although these pairings occur between
BBS4 and the two most common loci, thereby suggest-
ing that these associations may have been detected by
chance alone. The two most plausible molecular expla-
nations for the genetic phenomenon of triallelism are
(1) that the different BBS proteins interact directly with
each other and mutations in more than one member of
a multisubunit complex are required for disease or (2)
that the different BBS proteins operate in distinct but
complementary pathways. Dysfunction of one pathway
may be rescued by an alternative route, which, in turn,
would be compromised by the occurrence of additional
mutations. Regardless of which model may be shown
to be supported by further experimentation, description
of exclusive mutation pairings may assist in the eluci-
dation of important functional aspects of the different
BBS proteins.
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